<?xml version='1.0' encoding='utf-8'?>
<document id="26809959"><sentence text="Pralatrexate Monitoring Using a Commercially Available Methotrexate Assay to Avoid Potential Drug Interactions."><entity charOffset="0-12" id="DDI-PubMed.26809959.s1.e0" text="Pralatrexate" /><entity charOffset="55-67" id="DDI-PubMed.26809959.s1.e1" text="Methotrexate" /><pair ddi="false" e1="DDI-PubMed.26809959.s1.e0" e2="DDI-PubMed.26809959.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26809959.s1.e0" e2="DDI-PubMed.26809959.s1.e1" /></sentence><sentence text="Pralatrexate (PDX) is a folate antagonist structurally similar to methotrexate (MTX)"><entity charOffset="0-12" id="DDI-PubMed.26809959.s2.e0" text="Pralatrexate" /><entity charOffset="14-17" id="DDI-PubMed.26809959.s2.e1" text="PDX" /><entity charOffset="24-30" id="DDI-PubMed.26809959.s2.e2" text="folate" /><entity charOffset="66-78" id="DDI-PubMed.26809959.s2.e3" text="methotrexate" /><entity charOffset="80-83" id="DDI-PubMed.26809959.s2.e4" text="MTX" /><pair ddi="false" e1="DDI-PubMed.26809959.s2.e0" e2="DDI-PubMed.26809959.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26809959.s2.e0" e2="DDI-PubMed.26809959.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26809959.s2.e0" e2="DDI-PubMed.26809959.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26809959.s2.e0" e2="DDI-PubMed.26809959.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26809959.s2.e0" e2="DDI-PubMed.26809959.s2.e4" /><pair ddi="false" e1="DDI-PubMed.26809959.s2.e1" e2="DDI-PubMed.26809959.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26809959.s2.e1" e2="DDI-PubMed.26809959.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26809959.s2.e1" e2="DDI-PubMed.26809959.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26809959.s2.e1" e2="DDI-PubMed.26809959.s2.e4" /><pair ddi="false" e1="DDI-PubMed.26809959.s2.e2" e2="DDI-PubMed.26809959.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26809959.s2.e2" e2="DDI-PubMed.26809959.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26809959.s2.e2" e2="DDI-PubMed.26809959.s2.e4" /><pair ddi="false" e1="DDI-PubMed.26809959.s2.e3" e2="DDI-PubMed.26809959.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26809959.s2.e3" e2="DDI-PubMed.26809959.s2.e4" /></sentence><sentence text=" Unlike MTX, it is currently not known whether PDX exhibits delayed clearance and heightened toxicity in the setting of fluid overload"><entity charOffset="8-11" id="DDI-PubMed.26809959.s3.e0" text="MTX" /><entity charOffset="47-49" id="DDI-PubMed.26809959.s3.e1" text="PDX" /><pair ddi="false" e1="DDI-PubMed.26809959.s3.e0" e2="DDI-PubMed.26809959.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26809959.s3.e0" e2="DDI-PubMed.26809959.s3.e1" /></sentence><sentence text=" A specific serum assay for PDX is not commercially available"><entity charOffset="28-30" id="DDI-PubMed.26809959.s4.e0" text="PDX" /></sentence><sentence text=" To our knowledge, we report the first case using an MTX serum assay as a surrogate for PDX concentrations to avoid a potential drug-drug interaction with pralatrexate"><entity charOffset="155-167" id="DDI-PubMed.26809959.s5.e0" text="pralatrexate" /><entity charOffset="88-99" id="DDI-PubMed.26809959.s5.e1" text="PDX" /><entity charOffset="53-64" id="DDI-PubMed.26809959.s5.e2" text="MTX" /><pair ddi="false" e1="DDI-PubMed.26809959.s5.e2" e2="DDI-PubMed.26809959.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26809959.s5.e2" e2="DDI-PubMed.26809959.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26809959.s5.e2" e2="DDI-PubMed.26809959.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26809959.s5.e1" e2="DDI-PubMed.26809959.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26809959.s5.e1" e2="DDI-PubMed.26809959.s5.e0" /></sentence><sentence text=" We describe a 76-year-old man with refractory cutaneous T-cell lymphoma who began therapy with weekly PDX 15 mg/m(2) intravenous infusions on days 1, 8, and 15 of a 28-day cycle"><entity charOffset="103-105" id="DDI-PubMed.26809959.s6.e0" text="PDX" /></sentence><sentence text=" He subsequently developed mucositis, a moderate right-sided pleural effusion, and peripheral edema over the next 5 weeks" /><sentence text=" Aggressive diuresis with furosemide was initiated, which was then withheld the day before his next PDX dose to avoid a potential drug-drug interaction between PDX and furosemide"><entity charOffset="26-36" id="DDI-PubMed.26809959.s8.e0" text="furosemide" /><entity charOffset="168-178" id="DDI-PubMed.26809959.s8.e1" text="furosemide" /><entity charOffset="100-109" id="DDI-PubMed.26809959.s8.e2" text="PDX" /><entity charOffset="160-169" id="DDI-PubMed.26809959.s8.e3" text="PDX" /><pair ddi="false" e1="DDI-PubMed.26809959.s8.e0" e2="DDI-PubMed.26809959.s8.e0" /><pair ddi="false" e1="DDI-PubMed.26809959.s8.e0" e2="DDI-PubMed.26809959.s8.e2" /><pair ddi="false" e1="DDI-PubMed.26809959.s8.e0" e2="DDI-PubMed.26809959.s8.e3" /><pair ddi="false" e1="DDI-PubMed.26809959.s8.e0" e2="DDI-PubMed.26809959.s8.e1" /><pair ddi="false" e1="DDI-PubMed.26809959.s8.e2" e2="DDI-PubMed.26809959.s8.e2" /><pair ddi="false" e1="DDI-PubMed.26809959.s8.e2" e2="DDI-PubMed.26809959.s8.e3" /><pair ddi="false" e1="DDI-PubMed.26809959.s8.e2" e2="DDI-PubMed.26809959.s8.e1" /><pair ddi="false" e1="DDI-PubMed.26809959.s8.e3" e2="DDI-PubMed.26809959.s8.e3" /><pair ddi="false" e1="DDI-PubMed.26809959.s8.e3" e2="DDI-PubMed.26809959.s8.e1" /></sentence><sentence text=" His baseline MTX/PDX concentration (measured prior to administration of the cycle 2, week 2 PDX dose) was less than 0"><entity charOffset="18-20" id="DDI-PubMed.26809959.s9.e0" text="PDX" /><entity charOffset="93-95" id="DDI-PubMed.26809959.s9.e1" text="PDX" /><entity charOffset="14-16" id="DDI-PubMed.26809959.s9.e2" text="MTX" /><pair ddi="false" e1="DDI-PubMed.26809959.s9.e2" e2="DDI-PubMed.26809959.s9.e2" /><pair ddi="false" e1="DDI-PubMed.26809959.s9.e2" e2="DDI-PubMed.26809959.s9.e0" /><pair ddi="false" e1="DDI-PubMed.26809959.s9.e2" e2="DDI-PubMed.26809959.s9.e1" /><pair ddi="false" e1="DDI-PubMed.26809959.s9.e0" e2="DDI-PubMed.26809959.s9.e0" /><pair ddi="false" e1="DDI-PubMed.26809959.s9.e0" e2="DDI-PubMed.26809959.s9.e1" /></sentence><sentence text="20 μmol/L (i" /><sentence text="e" /><sentence text=", undetectable)" /><sentence text=" After PDX administration, his 1-hour peak MTX/PDX concentration increased to 0"><entity charOffset="7-9" id="DDI-PubMed.26809959.s13.e0" text="PDX" /><entity charOffset="47-49" id="DDI-PubMed.26809959.s13.e1" text="PDX" /><entity charOffset="43-45" id="DDI-PubMed.26809959.s13.e2" text="MTX" /><pair ddi="false" e1="DDI-PubMed.26809959.s13.e0" e2="DDI-PubMed.26809959.s13.e0" /><pair ddi="false" e1="DDI-PubMed.26809959.s13.e0" e2="DDI-PubMed.26809959.s13.e2" /><pair ddi="false" e1="DDI-PubMed.26809959.s13.e0" e2="DDI-PubMed.26809959.s13.e1" /><pair ddi="false" e1="DDI-PubMed.26809959.s13.e2" e2="DDI-PubMed.26809959.s13.e2" /><pair ddi="false" e1="DDI-PubMed.26809959.s13.e2" e2="DDI-PubMed.26809959.s13.e1" /></sentence><sentence text="58 μmol/L" /><sentence text=" Aggressive diuresis was withheld until his MTX/PDX concentration was undetectable, 43"><entity charOffset="48-50" id="DDI-PubMed.26809959.s15.e0" text="PDX" /><entity charOffset="44-46" id="DDI-PubMed.26809959.s15.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.26809959.s15.e1" e2="DDI-PubMed.26809959.s15.e1" /><pair ddi="false" e1="DDI-PubMed.26809959.s15.e1" e2="DDI-PubMed.26809959.s15.e0" /></sentence><sentence text="5 hours later" /><sentence text=" PDX is more potent than MTX and displays similar pharmacokinetic properties"><entity charOffset="1-3" id="DDI-PubMed.26809959.s17.e0" text="PDX" /><entity charOffset="25-27" id="DDI-PubMed.26809959.s17.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.26809959.s17.e0" e2="DDI-PubMed.26809959.s17.e0" /><pair ddi="false" e1="DDI-PubMed.26809959.s17.e0" e2="DDI-PubMed.26809959.s17.e1" /></sentence><sentence text=" PDX concentrations using the serum MTX assay reflect lower values than those reported from PDX-specific assays in clinical studies"><entity charOffset="1-3" id="DDI-PubMed.26809959.s18.e0" text="PDX" /><entity charOffset="92-94" id="DDI-PubMed.26809959.s18.e1" text="PDX" /><entity charOffset="36-38" id="DDI-PubMed.26809959.s18.e2" text="MTX" /><pair ddi="false" e1="DDI-PubMed.26809959.s18.e0" e2="DDI-PubMed.26809959.s18.e0" /><pair ddi="false" e1="DDI-PubMed.26809959.s18.e0" e2="DDI-PubMed.26809959.s18.e2" /><pair ddi="false" e1="DDI-PubMed.26809959.s18.e0" e2="DDI-PubMed.26809959.s18.e1" /><pair ddi="false" e1="DDI-PubMed.26809959.s18.e2" e2="DDI-PubMed.26809959.s18.e2" /><pair ddi="false" e1="DDI-PubMed.26809959.s18.e2" e2="DDI-PubMed.26809959.s18.e1" /></sentence><sentence text=" Because PDX is approved by the U"><entity charOffset="9-11" id="DDI-PubMed.26809959.s19.e0" text="PDX" /></sentence><sentence text="S" /><sentence text=" Food and Drug Administration for the treatment of uncommon malignancies, it is unlikely that a specific assay will be commercially developed" /><sentence text=" We propose that the MTX serum assay has merit for use in determining when to reinstate possible interacting drug therapies such as loop diuretics"><entity charOffset="21-24" id="DDI-PubMed.26809959.s22.e0" text="MTX" /></sentence><sentence text=" " /></document>